Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study - PubMed
Avatar

Ingentium, Inc. flipped this story into Multiple Sclerosis -- Ingentium, Inc.1900d